Difference between revisions of "Marotta LL, et al. J. Clin. Invest. (2011) cited as Ref 332 in DOI: 10.1038/s41392-020-0110-5 (Q9595)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: PubMed ID (P140): 21633165, #quickstatements; #temporary_batch_1590001671040)
(‎Created claim: Page(s) (P105): 2723-2735, #quickstatements; #temporary_batch_1590074839150)
 
(4 intermediate revisions by the same user not shown)
Property / Publication Date
 +
2011
Timestamp+2011-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2011 / rank
 +
Normal rank
Property / Published In Name String
 +
J. Clin. Invest.
Property / Published In Name String: J. Clin. Invest. / rank
 +
Normal rank
Property / Volume
 +
121
Property / Volume: 121 / rank
 +
Normal rank
Property / title
 +
The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English)
Property / title: The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English) / rank
 +
Normal rank
Property / Page(s)
 +
2723-2735
Property / Page(s): 2723-2735 / rank
 +
Normal rank

Latest revision as of 15:38, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Marotta LL, et al. J. Clin. Invest. (2011) cited as Ref 332 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Marotta LL
    0 references
    0 references
    2011
    0 references
    J. Clin. Invest.
    0 references
    121
    0 references
    The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English)
    0 references
    2723-2735
    0 references